Reivews:

Katsuki, T.; Martin, V. S. Org. React. 1996, 48, 1-300.

Johnson, R. A.; Sharpless, K. B. In *Catalytic Asymmetric Synthesis*, Ojima, I., Ed.; VCH: New York, **1993**, pp. 103–158.

Johnson, R. A.; Sharpless, K. B. In *Comprehensive Organic Synthesis*, Trost, B. M.; Fleming, I., Eds., Pergamon Press: New York, **1991**, *Vol.* 7, pp. 389–436.

Pfenninger, A. Synthesis 1986, 89-116.


Asymmetric Epoxidation of Allylic Alcohols:

$$R_2$$
 OH $Ti(Oi-Pr)_4$, (+)-DET R_2 OF R_3 OF t -BuOOH, 3Å-MS CH_2Cl_2 , -20 °C

- 5-10 mol% catalyst in the presence of 3- or 4Å-MS.
- (+)-DET = EtO_2C
- 10-20 mol% excess tartrate vs. Ti(OiPr)4 required.
- (+)- and (-)-DET are readily available and inexpensive.
- (+)- and (-)-DIPT, diisopropyl tartrate, are also available and sometimes lead to higher selectivity.

Gao, Y.; Hanson, R. M.; Klunder, J. M.; Ko, S. Y.; Masamune, H.; Sharpless, K. B. *J. Am. Chem. Soc.* **1987**, *109*, 5765–5780.

Mnemonic for selectivity:



Katsuki, T.; Sharpless, K. B. *J. Am. Chem. Soc.* **1980**, *102*, 5974–5976.

Application of Mnemonic:

Substitution patterns:

· Z-disubstituted olefins are least reactive and selective.

OH

Examples of Sharpless Epoxidation:

product	Ti(%)	tartarate(%)	°C	h	yield (%)	ee (%)
ОН	5	(+)-DIPT (6.0)	0	2	65	90
Ph OH	5	(+)-DIPT (7.0)	-20	3	89	>98
о Рr ОН	4.7	(+)-DET (5.9)	-12	11	88	95
OH C ₇ H ₁₅	10	(+)-DET (14)	-10	29	74	86
Ph OCH ₃	5	(+)-DIPT (7.5)	-35	2	79	>98
OCH ₃ OH	100	(+)-DET (142)	-20	14	80	80
BnO OH CH ₃ CH ₃	5	(+)-DET (7.4)	-20	0.75	95	91
Ph OH	120	(–)-DET (150)	-20	5	90	94

From: Gao, Y.; Hanson, R. M.; Klunder, J. M.; Ko, S. Y.; Masamune, H.; Sharpless, K. B. *J. Am. Chem. Soc.* **1987**, *109*, 5765-5780 and Johnson, R. A.; Sharpless, K. B. In *Catalytic Asymmetric Synthesis*, Ojima, I., Ed.; VCH: New York, **1993**, pp. 103–158.

M. Movassaghi

Chiral Substrate:

- · Products are diastereomeric.
- · Sense of induction is dominated by the catalyst.
- The C4 center reinforces and erodes this in "MATCHED" and "MISMATCHED" cases, respectively, as shown.

Ko, S. Y.; Lee, A. W. M.; Masamune, S.; Reed, L. A., III; Sharpless, K. B.; Walker, F. J. *Tetrahedron* **1990**. *46*. 245–264.

Homoallylic, bishomoallylic and trishomoallylic:

- Rates of epoxidation are usually slower.
- Enantiofacial selectivity of the catalyst is reversed for all three.
- Enantiofacial selectivity is generally lower.


Rossiter, B. E.; Sharpless, K. B. J. Org. Chem. 1984, 49, 3707–3711.

Hosokawa, T.; Kono, T.; Shinohara, T.; Murahashi, S.-I. *J. Organometal. Chem.* **1989**, *370*, C13–C16.

For other examples see: Johnson, R. A.; Sharpless, K. B. In *Catalytic Asymmetric Synthesis*, Ojima, I., Ed.; VCH: New York, **1993**, pp. 103-158.and Katsuki, T.; Martin, V. S. *Org. React.* **1996**, *48*, 1–300.

Kinetic Resolution:

- · Products are diastereomeric.
- Using the Sharpless mnemonic, contact between the C1 substituent (R) and the catalyst predicts the slow-reacting isomer.



- With the exception of Z-disubstituted allylic alcohols, $k_{rel} > 25$.
- When k_{rel} = 25, the ee of unreacted alcohol is essentially 100% at 60% conversion.
- Allylic tertiary alcohols are not successfully expoxidized under Sharpless conditions.
- Factors may combine for high selectivity:

- Disubstituted olefin is more reactive than monosubstituted olefin ($k_{rel} \sim 100$).
- k_{fast}/k_{slow} for chiral *E*-propenylcarbinols is ~100.

Excercice: Apply the Sharpless mnemonic to predict the stereochemistry of this product.

Sharpless, K. B.; Behrens, C. H.; Katsuki, T.; Lee, A. W. M.; Martin, V. S.; Takatani, M.; Viti, S. M.; Walker, F. J.; Woodard, S. S. *Pure Appl. Chem.* **1983**, *55*, 589–604.

Allylic 1,2-diols do not follow the Sharpless mnemonic:

Excercice: What isomer would you have predicted using the Sharpless mnemonic?

Takano, S.; Iwabuchi, Y.; Ogasawara, K. *J. Am. Chem.* Soc. **1991**, *113*, 2786–2787. M. Movassaqhi

C2-Symmetric Substrates:


• Any minor diastereomer that is produced is rapidly removed by bis-epoxidation.

Exercise: Why?

Schreiber, S. L.; Schreiber, T. S.; Smith, D. B. *J. Am. Chem. Soc.* **1987**, *109*, 1525–1529. Schreiber, S. L.; Goulet, M. T.; Schulte, G. *J. Am. Chem. Soc.* **1987**, *109*, 4718–4720.

Applications in Synthesis:

L-Hexoses:



Ko, S. Y.; Lee, A. W. M.; Masamune, S; Reed, L. A., III; Sharpless, K. B.; Walker, F. J. *Tetrahedron* **1990**, *46*, 245–264.

Venustatriol:

Corey, E. J.; Ha, D.-C. Tetrahedron Lett. 1988, 29, 3171-3174.

Venustatriol

M. Movassaghi

Ferensimycin B:

Evans, D. A.; Polniaszek, R. P.; DeVries, K. M.; Guinn, D. E.; Mathre, D. J. *J. Am. Chem. Soc.* **1991**, *113*, 7613–7630.

(-)-7-Deacetoxyalcyonin Acetate:

TMS

(-)-7-Deacetoxyalcyonin Acetate

MacMillan, D. W. C.; Overman, L, E. J. Am. Chem. Soc. 1995, 117, 10391-10392.

(+)-Neocarzinostatin Chromophore:

70%, ≥95% de

CH₃
OCH₃
OCH

 A further example of anomalous stereochemistry in AE of an allylic diol (no reaction with (–)-DIPT).

(+)-Neocarzinostatin Chromophore

Myers, A. G.; Hammond, M.; Wu, Y.; Xiang, J.-N.; Harrington, P. M.; Kuo, E. Y. *J. Am. Chem. Soc.* **1996**, *118*, 10006–10007.

Myers, A. G.; Liang, J.; Hammond, M.; Harrington, P. M.; Yusheng, W.; Kuo, E. Y. *J. Am. Chem. Soc.* **1998**, *120*, 5319–5320.

M. Movassaghi

Examples of the Sharpless Asymmetric Epoxidation Reaction in Industry:

(S,S)-Reboxetine succinate a norepinephrine uptake inhibitor

• In this example, excess TBHP was quenched with triethylphosphite instead of Fe^{II} sulfate.

Henegar, K. E.; Cebula, M. Org. Proc. Res. Dev. 2007, 11, 354-358.

• In the following example, the minor enantiomer was unreactive, leading to enantiomeric enrichment:

HIV-1 protease inhibitor

Jadhav, P. K.; Man, H. W. Tetrahedron Lett. 1996, 37, 1153-1156.

• In this example, a stoichiometric amount of titanium and DIPT was necessary for high conversion.

Gleave, D. M.; Brickner, S. J. J. Org. Chem. 1996, 61, 6470-6474.

Saksena, A. K.; Girijavallabhan, V. M.; Lovey, R. G.; Pike, R. E.; Desai, J. A.; Ganguly, A. K.; Hare, R. S.; Loebenberg, D.; Cacciapuoti, A.; Parmegiani, R. M. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 2023–2028.

$$\begin{array}{c} \text{CH}_{3} \\ \text{CH}_{3} \\ \text{CH}_{3} \\ \text{Geraniol} \end{array} \begin{array}{c} \text{CH}_{3} \\ \text{TBHP, 4Å-MS} \\ \text{CH}_{2}\text{Cl}_{2}, -10 \rightarrow 20 \, ^{\circ}\text{C} \\ 99\%, 91\% \, \text{ee} \end{array} \begin{array}{c} \text{CH}_{3} \\ \text{CH}_{4} \\ \text{CH}_{3} \\ \text{CH}_{4} \\ \text{CH}_{4} \\ \text{CH}_{4} \\ \text{CH}_{4} \\ \text{CH}_{4} \\ \text{CH}_{4} \\ \text{CH}_{5} \\ \text{CH}_{5} \\ \text{CH}_{5} \\ \text{CH}_{5} \\ \text{CH}$$

N-Boc-(2R,3R)-3-methyl-3-hydroxypipecolic acid

Noe, M. C.; Hawkins, J. M.; Snow, S. L.; Wolf-Gouveia, L. *J. Org. Chem.* **2008**, 73, 3295–3298.

Jesse Teske, Andy Flick, Daniel Schmitt